Kenvue (NYSE:KVUE) Issues FY 2025 Earnings Guidance

Kenvue (NYSE:KVUE) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 1.440-1.469 for the period, compared to the consensus EPS estimate of 1.250. The company issued revenue guidance of $15.3 billion-$15.6 billion, compared to the consensus revenue estimate of $15.9 billion.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.74 on Thursday. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a 50 day moving average price of $21.77 and a 200 day moving average price of $21.96. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $39.76 billion, a P/E ratio of 37.70, a PEG ratio of 2.05 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Sell-side analysts expect that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.